Plexus Corporation
PLXS
$261.71
+0.94%
Plexus Corp is a global electronics manufacturing services (EMS) provider that designs, manufactures, and services complex products for demanding regulatory environments, serving life-saving medical devices, mission-critical aerospace and defense products, industrial automation, and semiconductor capital equipment. The company differentiates itself through integrated lifecycle solutions spanning design, supply chain, manufacturing, and sustaining services, primarily targeting market leaders and disruptive innovators in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The current investor narrative centers on Plexus's strong revenue growth acceleration, driven by robust demand in its APAC segment and a rebound in industrial and semiconductor end markets, while margin expansion and free cash flow generation are key focal points for the stock's re-rating potential.…
PLXS
Plexus Corporation
$261.71
Investment Opinion: Should I buy PLXS Today?
Rating: Buy. Plexus offers a compelling risk/reward with accelerating revenue growth, improving margins, and a strong balance sheet, supported by analyst consensus and a 15.4% upside to the average target of $293.25.
Supporting evidence includes: (1) Revenue growth accelerating to 18.7% YoY, well above the industry average of ~8%; (2) Trailing P/E of 22.42x is below its 5-year average of ~25x, suggesting value; (3) PEG ratio of 0.40x indicates undervaluation relative to growth; (4) Operating margin expanded to 5.31% from 4.98% a year ago, demonstrating operating leverage. The company also has a low debt-to-equity ratio of 0.121 and positive free cash flow.
Risks to the thesis include valuation premium vs. peers (25% above industry P/E), cyclical exposure to semiconductor and industrial markets, and low gross margins that limit earnings buffer. This Buy rating would be downgraded to Hold if revenue growth decelerates below 10% or if gross margins fall below 9.5%. Upgrade to Strong Buy would require sustained margin expansion above 11% gross margin and a pullback to below $220. Overall, PLXS appears fairly valued relative to its own history but slightly overvalued vs. peers, with the growth trajectory justifying the premium.
Sign up to view all
PLXS 12-Month Price Forecast
Plexus is well-positioned with accelerating revenue growth, improving margins, and a strong balance sheet. The stock's valuation is reasonable relative to its growth rate, as evidenced by the low PEG ratio. However, the recent price pullback and cyclical end-market exposure warrant caution. The base case of 15% growth and stable margins supports the average target of $293.25. A bullish stance is justified by the growth momentum and analyst upgrades, but confidence is medium due to macro uncertainty. Upgrades would require sustained margin expansion; downgrades if growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Plexus Corporation's 12-month outlook, with a consensus price target around $293.25 and implied upside of +12.1% versus the current price.
Average Target
$293.25
0 analysts
Implied Upside
+12.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$258 - $330
Analyst target range
Plexus is covered by 4 analysts, with a consensus recommendation of 'Buy' (mean rating 2.2 on a 1-5 scale, where 1 is Strong Buy). The average target price is $293.25, implying 15.4% upside from the current price of $254.11. The distribution leans bullish: 3 Buy ratings (Stifel, Needham, Benchmark) and 1 Hold (Stifel previously, but recent upgrade to Buy). Recent actions include Stifel upgrading from Hold to Buy on April 20, 2026, and Needham and Benchmark maintaining Buy ratings. This consensus suggests analysts are optimistic about the company's growth trajectory and margin expansion.
The target price range spans from $258.00 (low) to $330.00 (high), a spread of $72 or 28% of the average target, indicating moderate uncertainty. The high target of $330.00 implies 29.8% upside and likely assumes continued revenue acceleration, margin expansion to above 11% gross margin, and multiple expansion to ~30x forward earnings. The low target of $258.00, just 1.5% above the current price, suggests downside risk from potential demand softening or margin compression. The recent upgrades (Stifel from Hold to Buy) signal improving sentiment, while the tight spread between low and current price indicates limited downside risk according to the most bearish analyst. Overall, the analyst community has strong conviction in the stock's upside potential.
Drowning in data?
Find the real signal!
Bulls vs Bears: PLXS Investment Factors
Plexus presents a compelling growth story with accelerating revenue (18.7% YoY), improving margins, and a strong balance sheet. The stock trades at a premium to industry peers but below its own historical average P/E, and the low PEG ratio (0.40x) suggests value relative to growth. However, the recent 13.9% monthly pullback and dependence on cyclical end markets introduce risk. The bull case is supported by analyst upgrades and a 15.4% upside to the average target, while the bear case centers on valuation premium and margin sensitivity. The single most important tension is whether the accelerating revenue growth can sustain and translate into continued margin expansion, justifying the premium valuation. Currently, the evidence slightly favors the bull case given the strong growth trajectory and low debt, but investors should monitor the upcoming earnings for confirmation.
Bullish
- Accelerating Revenue Growth: Q2 2026 revenue grew 18.73% YoY to $1.1638B, accelerating from 9.8% in Q2 2025 and 8.3% in Q3 2025. This strong momentum is driven by APAC segment demand in semiconductor and industrial automation.
- Improving Profitability and Margins: Operating margin expanded to 5.31% from 4.98% a year ago, and net income rose 27.5% YoY to $49.8M. Gross margin improved to 10.24% from 9.97%, showing operating leverage.
- Strong Balance Sheet with Low Debt: Debt-to-equity ratio is only 0.121, and free cash flow turned positive at $16.0M in Q2 2026 after negative FCF in Q1. Current ratio of 1.58 indicates ample liquidity.
- Attractive Valuation Relative to Growth: PEG ratio of 0.40x suggests the stock is undervalued relative to its earnings growth rate. Trailing P/E of 22.42x is below the 5-year average of ~25x, offering a discount to history.
Bearish
- Premium Valuation vs. Industry Peers: Trailing P/E of 22.42x is 25% above the industry average of ~18x, and EV/EBITDA of 13.49x is 23% above the industry average of ~11x. This premium may compress if growth decelerates.
- Recent Price Pullback and Momentum Weakness: Stock declined 13.87% in the past month, underperforming the S&P 500 by 14.47%. Current price is 17.3% below the 52-week high of $307.06, suggesting profit-taking or sector rotation.
- Low Gross Margins Typical of EMS Industry: Gross margin of 10.24% is typical for the EMS sector but leaves little room for error. Any cost inflation or pricing pressure could compress margins further, limiting earnings growth.
- Dependence on Cyclical End Markets: APAC segment (56% of revenue) is tied to semiconductor capital equipment and industrial automation, which are cyclical. A downturn in these markets could reverse the growth trajectory.
PLXS Technical Analysis
Plexus is in a sustained uptrend, with the stock up 88.86% over the past year, significantly outperforming the S&P 500's 20.92% gain. The current price of $254.11 sits at 82.8% of its 52-week range ($115.35 low to $307.06 high), indicating the stock is in the upper half of its range but has pulled back from recent highs, suggesting a potential consolidation phase rather than overextension. The 52-week high of $307.06 was set on June 18, 2026, and the current price is 17.3% below that peak, offering a possible entry point for momentum investors if the trend resumes.
Short-term momentum has diverged from the longer-term trend: the stock has declined 13.87% over the past month while the S&P 500 rose 0.6%, resulting in a relative strength of -14.47% over 1 month. However, the 3-month change remains strongly positive at +14.01%, and the 6-month change is +40.16%, indicating that the recent pullback may be a temporary correction within a broader uptrend. The 1-month decline contrasts sharply with the 1-year gain, suggesting profit-taking or sector rotation rather than a fundamental trend reversal, and the stock's beta of 0.879 implies lower volatility than the market, which may limit downside risk.
Key support is at the 52-week low of $115.35, though more immediate support lies near the $250 level, which was tested on July 15, 2026. Resistance is at the 52-week high of $307.06; a breakout above this level would signal a resumption of the uptrend and could target new highs. A breakdown below $250 would test the $230 area (April 2026 support). With a beta of 0.879, Plexus is less volatile than the S&P 500, meaning it may decline less in market downturns but also lag in strong rallies, which is consistent with its recent underperformance relative to the market over the past month.
Beta
0.88
0.88x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$115-$307
Price range past year
Annual Return
+95.6%
Cumulative gain past year
| Period | PLXS Return | S&P 500 |
|---|---|---|
| 1m | -9.3% | +0.6% |
| 3m | +3.0% | +3.4% |
| 6m | +50.4% | +7.1% |
| 1y | +95.6% | +16.4% |
| ytd | +71.9% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PLXS Fundamental Analysis
Plexus's revenue trajectory is accelerating, with Q2 2026 revenue of $1.1638 billion growing 18.73% year-over-year, up from 9.8% growth in Q2 2025 and 8.3% in Q3 2025. The sequential trend is also strong: Q2 2026 revenue increased 8.8% from Q1 2026's $1.0699 billion. Revenue is diversified across segments, with the APAC segment contributing $652.0 million (56% of total), Americas $397.0 million (34%), and EMEA $115.8 million (10%). The APAC segment is the primary growth driver, benefiting from semiconductor capital equipment and industrial automation demand. This accelerating growth supports the investment case for a cyclical recovery and market share gains.
Plexus is profitable with improving margins. Q2 2026 net income was $49.8 million, up 27.5% from $39.1 million in Q2 2025. Gross margin improved to 10.24% from 9.97% a year ago, though it remains below the 10.27% in Q4 2025. Operating margin expanded to 5.31% from 4.98% in Q2 2025, reflecting operating leverage. Net margin rose to 4.28% from 3.99% in the prior-year quarter. While gross margins are typical for the EMS industry (low double-digits), the sequential improvement and operating leverage are positive signals. The company does not pay dividends, reinvesting earnings into growth.
Plexus maintains a strong balance sheet with a debt-to-equity ratio of 0.121, indicating low leverage. Free cash flow (FCF) was $16.0 million in Q2 2026, recovering from negative FCF in Q1 2026 (-$50.6 million) due to working capital swings. Trailing twelve-month FCF is $75.8 million. The current ratio of 1.58 suggests adequate liquidity. Return on equity (ROE) is 11.9%, and return on assets (ROA) is 4.3%, both reasonable for the sector. The company generated $28.5 million in operating cash flow in Q2 2026, sufficient to cover capex of $12.5 million, indicating self-funding capacity. The low debt and positive FCF profile reduce financial risk.
Quarterly Revenue
$1.2B
2026-04
Revenue YoY Growth
+18.7%
YoY Comparison
Gross Margin
10.2%
Latest Quarter
Free Cash Flow
$75793000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PLXS Overvalued?
Since net income is positive ($49.8 million in Q2 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 22.42x, while the forward P/E is 26.83x, implying the market expects earnings growth. The forward P/E is higher than the trailing, suggesting investors are pricing in future earnings expansion, which aligns with the accelerating revenue trend. The PEG ratio of 0.40x (based on estimated EPS growth) indicates the stock may be undervalued relative to its growth rate, though this depends on the accuracy of growth estimates.
Compared to the industry (Hardware, Equipment & Parts), Plexus trades at a premium. The trailing P/E of 22.42x is above the industry average of approximately 18x (estimated), representing a 25% premium. The PS ratio of 0.96x is below the industry average of 1.5x, suggesting the premium is driven by profitability rather than sales. The EV/EBITDA of 13.49x is also above the industry average of ~11x, reflecting a 23% premium. This premium may be justified by Plexus's superior revenue growth (18.7% YoY vs. industry ~8%) and higher ROE (11.9% vs. industry ~10%).
Historically, Plexus's trailing P/E of 22.42x is near the middle of its 5-year range (roughly 12x to 40x). It is below the peak of 40x in Q2 2024 and above the trough of 12x in Q4 2022. The current P/E is below the 5-year average of ~25x, suggesting the stock is not overvalued relative to its own history. The PB ratio of 2.66x is also near the middle of its historical range (2.0x to 3.7x). This positioning implies the market is pricing in moderate growth expectations, not overly optimistic or pessimistic.
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Plexus's low gross margin of 10.24% is typical for EMS but leaves little buffer against cost increases; a 100bps compression would reduce net income by ~$11.6M based on Q2 revenue. The company's free cash flow was negative in Q1 2026 (-$50.6M) due to working capital swings, though it recovered to $16M in Q2. Debt is minimal (D/E 0.121), but the reliance on APAC (56% of revenue) creates concentration risk if semiconductor demand weakens. Revenue growth of 18.7% YoY is strong, but if it decelerates, the forward P/E of 26.8x could contract.
Market & Competitive Risks: The stock's beta of 0.879 suggests lower volatility than the market, but the recent 13.9% monthly decline shows it is not immune to sector rotation. The trailing P/E of 22.42x is a 25% premium to the industry average, making it vulnerable to multiple compression if growth disappoints. Competitive pressures from larger EMS providers like Foxconn or Flex could erode market share. No recent news highlights specific threats, but the cyclical nature of semiconductor and industrial end markets poses macro risk.
Worst-Case Scenario: A sharp downturn in semiconductor capital equipment demand, combined with margin compression from rising costs, could cause revenue to decline and earnings to miss estimates. Analysts would likely downgrade the stock, pushing the price toward the 52-week low of $115.35. From the current price of $254.11, this represents a potential loss of -54.6%. The bear-case analyst target of $258.00 implies only 1.5% upside, but in a severe recession, the stock could revisit its historical trough valuation of ~12x P/E, corresponding to a price around $124 based on trailing EPS of $10.36.
FAQ
The key risks are: (1) Cyclical exposure: 56% of revenue comes from APAC, tied to semiconductor and industrial automation, which are cyclical. A downturn could sharply reduce growth. (2) Margin sensitivity: Gross margins of 10.24% are thin; a 100bps compression would reduce net income by ~$11.6M. (3) Valuation premium: The P/E is 25% above the industry average, making the stock vulnerable to multiple compression if growth disappoints. (4) Limited analyst coverage: Only 4 analysts cover the stock, leading to potential volatility on earnings surprises. The most severe risk is a recession that could push the stock to the 52-week low of $115.35, a 54.6% loss from current levels.
The 12-month forecast is moderately bullish. The base case (50% probability) expects revenue growth of 15-18% and stable margins, driving the stock to the average analyst target of $293.25, a 15.4% gain. The bull case (30% probability) sees growth accelerating above 20% and margins expanding above 11%, pushing the stock to $330 (29.8% upside). The bear case (20% probability) involves a cyclical downturn slowing growth to single digits, with the stock falling to $258 or lower, potentially revisiting the 52-week low of $115.35. The most likely scenario is the base case, assuming continued demand in semiconductor and industrial markets. Key assumptions include no major macro recession and sustained margin improvement.
PLXS is fairly valued relative to its own history but slightly overvalued compared to industry peers. The trailing P/E of 22.42x is below the 5-year average of ~25x, suggesting it is not overvalued historically. However, it trades at a 25% premium to the industry average P/E of ~18x, reflecting the market's expectation of above-average growth. The PEG ratio of 0.40x indicates the stock is undervalued relative to its estimated EPS growth, implying the market is not fully pricing in the growth potential. The PS ratio of 0.96x is below the industry average of 1.5x, which is a positive sign. Overall, the valuation implies the market expects continued revenue acceleration and margin expansion, which seems reasonable given the current trajectory.
PLXS appears to be a good buy for growth-oriented investors with a moderate risk tolerance. The stock offers a 15.4% upside to the average analyst target of $293.25, supported by accelerating revenue growth of 18.7% YoY and a low PEG ratio of 0.40x, which suggests it is undervalued relative to its earnings growth. However, the trailing P/E of 22.42x is a 25% premium to the industry average, so it is not a deep value play. The biggest downside risk is a cyclical downturn in semiconductor and industrial markets, which could reverse growth. For long-term investors, the strong balance sheet (D/E 0.121) and improving margins provide a cushion. It is a buy for those who believe the growth trajectory will continue, but not for those seeking immediate income or low volatility.
PLXS is better suited for long-term investment given its growth trajectory and cyclical nature. The stock has a beta of 0.879, indicating lower volatility than the market, but it has experienced a 13.9% monthly decline, showing short-term risk. The company does not pay a dividend, so returns come from capital appreciation. With accelerating revenue growth and a strong balance sheet, a minimum holding period of 2-3 years is recommended to ride out cyclical fluctuations. Short-term traders could capitalize on momentum, but the recent pullback and wide analyst target spread ($258-$330) add uncertainty. Long-term investors benefit from the PEG ratio of 0.40x, which suggests the stock is undervalued relative to its growth potential.
